Acadia Pharma (ACAD) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $19.73 -2.86%
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -52.4%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.72), $0.01 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $15.29 million versus the consensus estimate of $15.19 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
